Amaryl Tablets (Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 4, 2017 Category: Drugs & Pharmacology Source Type: news

Avandaryl (Rosiglitazone Maleate and Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Amaryl (glimepiride)
Title: Amaryl (glimepiride)Category: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 9/16/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 16, 2016 Category: Endocrinology Source Type: news

Amaryl (Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 13, 2016 Category: Drugs & Pharmacology Source Type: news

New oral diabetes drugs may also protect patients' kidney health
In a clinical trial of patients with type 2 diabetes, canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea), while having similar blood sugar –lowering effects, report investigators. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 19, 2016 Category: Science Source Type: news

Risk of low blood sugar differs among similar diabetes drugs
Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs -- which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide -- stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 19, 2016 Category: Science Source Type: news

Empagliflozin surpasses glimepiride as metformin add-on
NEW ORLEANS – When used as an add-on therapy to metformin in patients with type 2 diabetes mellitus, empagliflozin has sustained safety and efficacy in reducing in hemoglobin A1c... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 24, 2016 Category: Endocrinology Source Type: news

Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk Warfarin, Sulfonylurea Combo Ups Severe Hypoglycemia Risk
The findings suggest a unique drug-drug interaction between warfarin and glipizide/glimepiride, with the greatest hypoglycemia risk at start of warfarin treatment. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Myocardial injury without electrocardiographic changes after a suicide attempt by an overdose of glimepiride and zolpidem: a case report and literature review - Chou S, Ayabe S, Sekine N.
A 40-year-old diabetic man was admitted to our hospital for poor glycemic control. During hospitalization, he took 42 mg glimepiride and 50 mg zolpidem as a suicide attempt. The following day, the creatine kinase-MB fraction and troponin I levels were elev... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 8, 2015 Category: Global & Universal Tags: Poisoning Source Type: news

glimepiride, Amaryl
Title: glimepiride, AmarylCategory: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 8/4/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 4, 2015 Category: Drugs & Pharmacology Source Type: news

NPPA brings 39 more drugs under price control
The prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride have been fixed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 16, 2015 Category: Pharmaceuticals Source Type: news

NPPA fixes price of 39 drug formulation packs
As per the notification the prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride has been fixed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 15, 2015 Category: Pharmaceuticals Source Type: news

Diabetes drug is activated by light to cause pancreas to release insulin
Scientists have developed a “photoswitchable” version of the diabetes drug glimepiride that is activated through exposure to blue light, allowing insulin release by pancreatic cells to be optically controlled. Pharmaceutical Journal (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 20, 2014 Category: Endocrinology Source Type: news

Empagliflozin Useful Second-Line for Diabetes vs GlimepirideEmpagliflozin Useful Second-Line for Diabetes vs Glimepiride
The SGLT2 inhibitor empagliflozin provided favorable results at 2 years compared with the sulfonylurea glimepiride when used as second-line therapy after metformin in diabetes. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 17, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Prices of 108 diabetes, cardiac formulations fixed: NPPA
The drugs that will become cheaper would include atorvastatin, gliclazide, glimepiride, heparin and metolazone among others. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 14, 2014 Category: Pharmaceuticals Source Type: news

Great CPC: Metformin toxicity
3.5 out of 5 stars Case 23-2013: a 54-Year-old Woman with Abdominal Pain, Vomiting, and Confusion. Kalantar-Zadeh K et al. N Engl J Med 2013 Jul 25;369:374-382. Full Text This is a very instructive case discussion from the Massachusetts General Hospital. A plane was diverted to Boston because one passenger, a 54-year-old woman, developed increasing abdominal pain and vomiting, along with decreasing mental status. After the plane landed, EMS found that here vital signs were fairly unremarkable (HR = 52 bpm). She was not hypoglycemic. Her medical history included type-2 diabetes, hypertension, and chronic renal disease....
Source: The Poison Review - July 26, 2013 Category: Toxicology Authors: Leon Tags: Medical acute pancreatitis anion gap metabolic acidosis case discussion case records of the massachusetts general hospital metformin toxicity Source Type: news

More Data Will Inform Place of SGLT2 Inhibitors in DiabetesMore Data Will Inform Place of SGLT2 Inhibitors in Diabetes
A comparison of canagliflozin with glimepiride as an add-on to metformin in type 2 diabetes adds some knowledge to help guide use of the new SGLT2 inhibitors. But more will be needed, says an editorial. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes And Mild Renal Impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA® (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with Type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia, and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2013 Category: Global & Universal Source Type: news